Literature DB >> 19553108

Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors.

Yongmun Choi1, Farisa Syeda, John R Walker, Patrick J Finerty, Dominic Cuerrier, Amy Wojciechowski, Qingsong Liu, Sirano Dhe-Paganon, Nathanael S Gray.   

Abstract

The Eph family of receptor tyrosine kinases has drawn growing attention due to their role in regulating diverse biological phenomena. However, pharmacological interrogation of Eph kinase function has been hampered by a lack of potent and selective Eph kinase inhibitors. Here we report the discovery of compounds 6 and 9 using a rationally designed kinase-directed library which potently inhibit Eph receptor tyrosine kinases, particularly EphB2 with cellular EC(50)s of 40nM. Crystallographic data of EphA3 and EphA7 in complex with the inhibitors show that they bind to the 'DFG-out' inactive kinase conformation and provide valuable information for structure-based design of second generation inhibitors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19553108      PMCID: PMC2730633          DOI: 10.1016/j.bmcl.2009.05.029

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  22 in total

1.  An efficient rapid system for profiling the cellular activities of molecular libraries.

Authors:  Jonathan S Melnick; Jeff Janes; Sungjoon Kim; Jim Y Chang; Daniel G Sipes; Drew Gunderson; Laura Jarnes; Jason T Matzen; Michael E Garcia; Tami L Hood; Ronak Beigi; Gang Xia; Richard A Harig; Hayk Asatryan; S Frank Yan; Yingyao Zhou; Xiang-Ju Gu; Alham Saadat; Vicki Zhou; Frederick J King; Christopher M Shaw; Andrew I Su; Robert Downs; Nathanael S Gray; Peter G Schultz; Markus Warmuth; Jeremy S Caldwell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

2.  Autoregulation by the juxtamembrane region of the human ephrin receptor tyrosine kinase A3 (EphA3).

Authors:  Tara L Davis; John R Walker; Peter Loppnau; Christine Butler-Cole; Abdellah Allali-Hassani; Sirano Dhe-Paganon
Journal:  Structure       Date:  2008-06       Impact factor: 5.006

3.  A general strategy for creating "inactive-conformation" abl inhibitors.

Authors:  Barun Okram; Advait Nagle; Francisco J Adrián; Christian Lee; Pingda Ren; Xia Wang; Taebo Sim; Yongping Xie; Xing Wang; Gang Xia; Glen Spraggon; Markus Warmuth; Yi Liu; Nathanael S Gray
Journal:  Chem Biol       Date:  2006-07

4.  Rational design of inhibitors that bind to inactive kinase conformations.

Authors:  Yi Liu; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2006-07       Impact factor: 15.040

Review 5.  Discovery of a novel Raf kinase inhibitor.

Authors:  J F Lyons; S Wilhelm; B Hibner; G Bollag
Journal:  Endocr Relat Cancer       Date:  2001-09       Impact factor: 5.678

6.  EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers.

Authors:  Alessandro Lugli; Hanspeter Spichtin; Robert Maurer; Martina Mirlacher; Jeff Kiefer; Pia Huusko; David Azorsa; Luigi Terracciano; Guido Sauter; Olli-P Kallioniemi; Spyro Mousses; Luigi Tornillo
Journal:  Clin Cancer Res       Date:  2005-09-15       Impact factor: 12.531

7.  NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia.

Authors:  Shinya Kimura; Haruna Naito; Hidekazu Segawa; Junya Kuroda; Takeshi Yuasa; Kiyoshi Sato; Asumi Yokota; Yuri Kamitsuji; Eri Kawata; Eishi Ashihara; Yohei Nakaya; Haruna Naruoka; Tatsushi Wakayama; Kimio Nasu; Tetsuo Asaki; Tomoko Niwa; Kazuko Hirabayashi; Taira Maekawa
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

8.  EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer.

Authors:  Weiguang Mao; Elizabeth Luis; Sarajane Ross; Johnny Silva; Christine Tan; Craig Crowley; Clarissa Chui; Gretchen Franz; Peter Senter; Hartmut Koeppen; Paul Polakis
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

9.  The phosphorylation of EphB2 receptor regulates migration and invasion of human glioma cells.

Authors:  Mitsutoshi Nakada; Jared A Niska; Hisashi Miyamori; Wendy S McDonough; Jie Wu; Hiroshi Sato; Michael E Berens
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

Review 10.  The Eph receptor/ephrin system: an emerging player in the invasion game.

Authors:  Tessa N Campbell; Stephen M Robbins
Journal:  Curr Issues Mol Biol       Date:  2008       Impact factor: 2.081

View more
  46 in total

Review 1.  Targeting Eph receptors with peptides and small molecules: progress and challenges.

Authors:  Roberta Noberini; Ilaria Lamberto; Elena B Pasquale
Journal:  Semin Cell Dev Biol       Date:  2011-10-25       Impact factor: 7.727

Review 2.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Authors:  Elena B Pasquale
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

Review 3.  Therapeutic targeting of EPH receptors and their ligands.

Authors:  Andrew W Boyd; Perry F Bartlett; Martin Lackmann
Journal:  Nat Rev Drug Discov       Date:  2014-01       Impact factor: 84.694

4.  Affinity reagents that target a specific inactive form of protein kinases.

Authors:  Pratistha Ranjitkar; Amanda M Brock; Dustin J Maly
Journal:  Chem Biol       Date:  2010-02-26

5.  Discovery of a novel chemotype of tyrosine kinase inhibitors by fragment-based docking and molecular dynamics.

Authors:  Hongtao Zhao; Jing Dong; Karine Lafleur; Cristina Nevado; Amedeo Caflisch
Journal:  ACS Med Chem Lett       Date:  2012-08-23       Impact factor: 4.345

6.  Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases.

Authors:  Jing Dong; Hongtao Zhao; Ting Zhou; Dimitrios Spiliotopoulos; Chitra Rajendran; Xiao-Dan Li; Danzhi Huang; Amedeo Caflisch
Journal:  ACS Med Chem Lett       Date:  2014-09-29       Impact factor: 4.345

Review 7.  Eph receptor tyrosine kinases in cancer stem cells.

Authors:  Jin Chen; Wenqiang Song; Katherine Amato
Journal:  Cytokine Growth Factor Rev       Date:  2014-05-17       Impact factor: 7.638

8.  Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors.

Authors:  Lixin Qiao; Sungwoon Choi; April Case; Thomas G Gainer; Kathleen Seyb; Marcie A Glicksman; Donald C Lo; Ross L Stein; Gregory D Cuny
Journal:  Bioorg Med Chem Lett       Date:  2009-09-09       Impact factor: 2.823

9.  Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis.

Authors:  Birgit Mosch; Bettina Reissenweber; Christin Neuber; Jens Pietzsch
Journal:  J Oncol       Date:  2010-03-10       Impact factor: 4.375

10.  Pharmacological inhibition of Eph receptors enhances glucose-stimulated insulin secretion from mouse and human pancreatic islets.

Authors:  R Jain; D Jain; Q Liu; B Bartosinska; J Wang; D Schumann; S G Kauschke; P Eickelmann; L Piemonti; N S Gray; E Lammert
Journal:  Diabetologia       Date:  2013-03-09       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.